BahiaFarma, Biocon Biologics Ltd, and Bionovis signed a memorandum of understanding (MoU) on Saturday to collaborate on developing a medication. The MoU was signed in the presence of Brazilian President Luiz Inacio Lula da Silva and Commerce and Industry Minister Piyush Goyal at Ficci's India-Brazil Business Forum. The agreement was established for the advancement of Pertuzumab, designated for HER-2 metastatic breast cancer. A new MoU was established among NMDC Ltd, Vale SA, and Adani Gangavaram Port Ltd to enhance collaboration in developing a facility within a Special Economic Zone (SEZ) framework at the Port of Gangavaram, aimed at blending and marketing iron ore fines. NMDC will provide low-grade ore, Vale will provide high-grade ore, while AGPL will oversee port infrastructure, blending zones, loading and unloading operations, yard management, acquiring licenses, and performing blending as per the technical specifications of the involved parties. The MoU is effective for 12 months and can be extended for another 12 months. The project's worth is approximately USD 500 million. An MoU was signed between Farmanguinhos/Fiocruz and Biocon Pharma Ltd to establish R&D in key pharmaceutical ingredients and medications for SUS, focusing on rare diseases, oncology, and immunosuppressants.